Table 2.

Benefits and Costs of PrEP Strategies Over 20 Years – General MSM Population

									ICER Relative to§
Strategy*	New HIV Infections¶	HIV Infections Prevented†	HIV Prevalence at 20 Years	Total Costs of PrEP (billions) ¥#	Total Costs (billions)¥	Total QALYs¥	Incremental Costs¥‡ (billions)	Incremental QALYs¥‡	No PrEP	Next Lower Level of PrEP
100% Start PrEP	242,627	249,156 (51%)	6.4%	$495	$1,366	117,488,043	$480	2,217,732	$216,480	$253,645
50% Start PrEP	348,492	143,291 (29%)	7.9%	$247	$1,124	116,533,983	$238	1,263,673	$188,421	$201,012
20% Start PrEP	429,025	62,759 (13%)	9.0%	$98	$980	115,820,477	$95	550,166	$172,091	$172,091
Status Quo (No PrEP)	491,784		9.9%		$886	115,270,310

^*PrEP = preexposure prophylaxis.

^¶New HIV infections and HIV infections prevented are undiscounted totals. Discounting infections at 3% annually reduces the number of infections averted for each strategy by approximately 22%.

^†The values in parentheses are the fraction of total HIV infections prevented.

^¥Costs and quality-adjusted life years (QALYs) are net present values (3% annual discount rate) over 20 years.

^#Total costs of PrEP include the cost of antiretroviral drugs for PrEP, costs of monitoring tests and physician visits, and initiation and discontinuation costs.

^‡Incremental costs and QALYs are relative to the status quo.

^§ICER = Incremental cost-effectiveness ratio, relative to the status quo of no PrEP use or the next lower level of PrEP use (i.e., the PrEP use scenario in the row below, with a lower percentage of MSM starting PrEP).